ZF2001

The Chinese biopharmaceutical Group Anhui Zhifei Longcom Biologic Pharmacy has developed ZF2001, a vaccine composed of protein subunits, a molecule from the binding region with the host cell. This technique includes pieces of the viral Spike protein of the SARS-CoV-2 virus, instead of including the full pathogen. The organism recognizes this alien protein, producing T lymphocytes and antibodies that will provide a memory effect able to fight the virus causing covid-19 in case we get infected in the future.

Phase III of the clinical trial of ZF2001 started in December 2020 and has the support of 29,000 volunteers from China, Ecuador, Indonesia, Pakistan, and Uzbekistan. 

The vaccine has been approved by China and Uzbekistan, but it has yet to be determined if it will be administered in two or three doses. Likewise, no data about its efficacy have been published.

Results from phases I and II discarded serious adverse reactions.

The manufacturer has not provided details about the temperature needed to preserve this vaccine.